Buoyed by the profit growth, Square Pharma’s board has recommended a 110 percent cash dividend, its highest in nine years

Square Pharmaceuticals Ltd recorded Tk 1,465 crore profit in the July-March period of the ongoing financial year, up around 9 percent year-on-year

Production of active pharmaceutical ingredients (APIs) at the API Industrial Park in Gazaria of Munshiganj will begin next month, with ACME Laboratories set to commission its manufacturing unit despite the lack of gas supply.

Square Pharmaceuticals registered a 4.53 percent year-on-year growth in profit to Tk 1,898 crore

Square Pharmaceuticals Ltd, the country’s biggest drug maker, has announced today its plan to invest Tk 400 crore for expansion. The funds would be used for BMRE (Balancing, Modernisation, Rehabilitation and Expansion), and the purchase of capital machinery and land for the future expansion of its business.

Square Pharmaceuticals PLC has struck a contract manufacturing agreement with Euro Pharma Ltd.

Square Pharma today said its profit growth slowed down in the first quarter of the financial year ending on September 30 as its operating expenses soared.